Volume : 11, Issue : 02, February – 2024

Title:

A REVIEW ARTICLE ON TALAZOPARIB – ANTI CANCER DRUG

Authors :

R. Jona Methusala, N. Sai Haritha

Abstract :

Talazoparib tosylate (BMN-673, Talzenna; Pfizer) is an oral poly [ADP-ribose] polymerase (PARP) inhibitor (PARPi) that has been approved by the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) for the treatment of germline BRCA-mutated locally advanced or metastatic breast cancer (BC). In preclinical and clinical studies, talazoparib exerted superior efficacy and offered a significant clinical benefit in advanced or metastatic BC patients harbouring germline BRCA mutations compared with other PARPi and standard chemotherapy regimens through the concept of synthetic lethality. Thus, this review provides insight into the results of preclinical and clinical studies, highlights the current challenges of talazoparib and suggests innovative approaches to further improve its clinical efficacy and expand the use of talazoparib in advanced BC and/or triple-negative BC treatments beyond BRCA mutations.
Keywords: BMN-673; BRCA-positive breast cancer; Cancer therapy; Poly [ADP-ribose] polymerase (PARP) inhibitors; Talazoparib to sylate.

Cite This Article:

Please cite this article in press N. Sai Haritha et al., A Review Article On Talazoparib – Anti Cancer Drug, Indo Am. J. P. Sci, 2024; 11 (02).

Number of Downloads : 10

References:

1. Shall S. Proceedings: Experimental manipulation of the specific activity of poly(ADP-ribose) polymerase. J Biochem (Tokyo). 1975 Jan 1;77(1?):2p. pmid:166073
2. Purnell MR, Whish WJ. Novel inhibitors of poly(ADP-ribose) synthetase. Biochem J. 1980 Mar 1;185(3):775–7. pmid:6248035
3. Terada M, Fujiki H, Marks PA, Sugimura T. Induction of erythroid differentiation of murine erythroleukemia cells by nicotinamide and related compounds. Proc Natl Acad Sci U S A. 1979 Dec;76(12):6411–4. pmid:230509
4. Shen Y, Rehman FL, Feng Y, Boshuizen J, Bajrami I, Elliott R, et al. BMN 673, a novel and highly potent PARP1/2 inhibitor for the treatment of human cancers with DNA repair deficiency. Clin Cancer Res Off J Am Assoc Cancer Res. 2013 Sep 15;19(18):5003–15. pmid:23881923
5. Rose M, Burgess JT, O’Byrne K, Richard DJ, Bolderson E. PARP Inhibitors: Clinical Relevance, Mechanisms of Action and Tumor Resistance. Front Cell Dev Biol. 2020 Sep 9;8:564601. pmid:33015058
6. Dockery LE, Gunderson CC, Moore KN. Rucaparib: the past, present, and future of a newly approved PARP inhibitor for ovarian cancer. OncoTargets Ther. 2017;10:3029–37.
7. CurtinNJ,SzaboC.TherapeuticapplicationsofPARPinhibitors:anticancertherapyand beyond. Mol Aspects Med. 2013 Dec;34(6):1217–56. pmid:23370117
8. Murai J, Huang SN, Das BB, Renaud A, Zhang Y, Doroshow JH, et al. Trapping of PARP1 and PARP2 by Clinical PARP Inhibitors. Cancer Res. 2012 Nov 1;72(21):5588–99. pmid:23118055
9. Zhou Y, Tang S, Chen T, Niu M-M. Structure-Based Pharmacophore Modeling, Virtual Screening, Molecular Docking and Biological Evaluation for Identification of Potential Poly (ADP-Ribose) Polymerase-1 (PARP-1) Inhibitors. Molecules. 2019; 24(23):4258.
10. GriguoloG,DieciMV,GuarneriV,ConteP.Olaparibforthetreatmentofbreastcancer.
Expertreviewofanticancer therapy.2018Jun3;18(6):519–30.pmid:29582690
11. Mirza MR, Monk BJ, Herrstedt J, Oza AM, Mahner S, Redondo A, et al. Niraparib maintenancetherapy in platinum-sensitive, recurrent ovarian cancer. NewEngland Journal of Medicine. 2016 Dec 1;375(22):2154–64. pmid:27717299
12. HopkinsT.A.,AinsworthW.B.,EllisP.A.,DonawhoC.K.,DiGiammarinoE.L.,Panchal
S. C.,etal.(2019). PARP1 trapping by PARPinhibitorsdrivescytotoxicityin both cancer cells andhealthybone marrow. Molecular Cancer Research, 17(2), 409–419. pmid:30429212
13. Irwin JJ, Tang KG, Young J, Dandarchuluun C, Wong BR, Khurelbaatar M, et al. ZINC20— A Free Ultralarge-Scale Chemical Database for Ligand Discovery. J Chem Inf Model. 2020; 60(12):6065–73. pmid:33118813
14. Baell JB, Holloway GA. New Substructure Filters for Removal of Pan Assay Interference Compounds (PAINS) from Screening Libraries and for Their Exclusion in Bioassays. J Med Chem. 2010 Apr 8;53(7):2719–40. pmid:20131845
15. Hawkins PCD, Skillman AG, Nicholls A. Comparison of Shape-Matching and Docking as Virtual Screening Tools. J Med Chem. 2007 Jan 1;50(1):74–82. pmid:17201411
16. Abagyan R, Totrov M, Kuznetsov D. ICM—A new method for protein modeling and design: Applications to docking and structure prediction from the distorted native conformation. J Comput Chem. 1994;15(5):488–506.
17. Cross JB, Thompson DC, Rai BK, Baber JC, Fan KY, Hu Y, et al. Comparison of Several Molecular Docking Programs: Pose Prediction and Virtual Screening Accuracy. J Chem Inf Model. 2009 Jun 22; 49(6):1455–74.
18. ChilingaryanG, AbelyanN, SargsyanA, NazaryanK, SerobianA, ZakaryanH. Combination of consensus and ensemble docking strategies for the discovery of human dihydroorotate dehydrogenase inhibitors. Sci Rep. 2021 Jun 1;11(1):11417. pmid:34075175
19. Neves MAC, Totrov M, Abagyan R. Docking and scoring with ICM: the benchmarking results and strategies for improvement. J Comput Aided Mol Des. 2012; 26(6):675–86. pmid:22569591
20. SahakyanH.ImprovingvirtualscreeningresultswithMM/GBSAandMM/PBSArescoring.
JournalofComputer-AidedMolecularDesign.2021Jun;35(6):731–6. pmid:33983518
21. Wang J, Wolf RM, Caldwell JW, Kollman PA, Case DA. Development and testing of a general amber force field. J Comput Chem. 2004;25(9):1157–74. pmid:15116359
22. Jakalian A, Jack DB, Bayly CI. Fast, efficient generation of high-quality atomic charges. AM1-BCC model: II. Parameterization and validation. J Comput Chem. 2002; 23(16):1623–
41.pmid:12395429
23. Maier JA, Martinez C, Kasavajhala K, Wickstrom L, Hauser KE, Simmerling C. ff14SB: Improving the Accuracy of Protein Side Chain and Backbone Parameters from ff99SB. J Chem Theory Comput. 2015 Aug 11; 11(8):3696–713. pmid:26574453
24. Case DA, Cheatham TE III, Darden T, Gohlke H, Luo R, Merz KM Jr, et al. The Amber biomolecular simulation programs. Journal of computational chemistry. 2005 Dec;26(16):1668–88. pmid:16200636
25. Jorgensen WL, Chandrasekhar J, Madura JD, Impey RW, Klein ML. Comparison of simple potential functions for simulating liquid water. The Journal of chemical physics. 1983 Jul 15;79(2):926–35.
26. Oliver DS, Cunha LB, Reynolds AC. Markov chain Monte Carlo methods for conditioning a permeability field to pressure data. Mathematical geology. 1997 Mar;29(1):61–91.
27. WuX,BrooksBR.Self-guidedLangevindynamicssimulationmethod.ChemicalPhysics Letters. 2003 Nov 14;381(3–4):512–8.
28. Miller BR III, McGee TD Jr, Swails JM, Homeyer N, Gohlke H, Roitberg AE. MMPBSA.py:an efficient programfor end-statefree energycalculations. Journal of chemicaltheoryand computation. 2012 Sep 11;8(9):3314–21. pmid:26605738
29. https://www.pharmacologyjournal.in/…/2-1-13-780.pdf
30. MuraiJ, HuangSY, DasBB,etal.TrappingofPARP1andPARP2byclinicalPARPinhibitors. Cancer Res 2012;72:5588-5599.
31. MuraiJ, HuangSY, RenaudA,etal.StereospecificPARPtrappingbyBMN673and comparison with olaparib and rucaparib. Mol Cancer Ther 2014;13:433-443.
32. Rouleau M,Patel A, Hendzel MJ, Kaufmann SH,PoirierGG. PARP inhibition: PARP1 and beyond. Nat Rev Cancer 2010;10:293-301.
33. Shen Y, Rehman FL,Feng Y, et al. BMN 673, a novel and highly potent PARP1/2 inhibitor forthetreatmentofhumancancerswithDNArepairdeficiency.ClinCancerRes 2013;19:5003-5015.
34. de Bono J, Ramanathan RK, Mina L, et al. Phase I, dose-escalation, two-part trial of thePARP inhibitor talazoparib in patients with advanced germline BRCA1/2 mutations and selected sporadic cancers. Cancer Discov 2017;7:620-629.
35. Turner NC,Telli ML, Rugo HS, et al. Final results of a phase 2 study of talazoparib (TALA) following platinum or multiple cytotoxic regimens in advanced breast cancer patients (pts) with germline BRCA1/2 mutations (ABRAZO). Presented at the American Society ofClinical Oncology 2017 Annual Meeting, Chicago, June 2–6, 2017. abstract.
GoogleScholar.opens in newtab
36. HaybittleJL.Repeatedassessmentofresultsinclinicaltrialsofcancertreatment.BrJ Radiol 1971;44:793-797.
37. Peto R, Pike MC, Armitage P, et al. Design and analysis of randomized clinical trials requiringprolongedobservationofeachpatient.I.Introductionanddesign.BrJ Cancer 1976;34:585-612.
38. OsobaD, RodriguesG, MylesJ, ZeeB, PaterJ.Interpretingthesignificanceofchangesin health-related quality-of-life scores. J Clin Oncol 1998;16:139-144.
39. Robson M, Im S-A, Senkus E, et al. Olaparib formetastatic breast cancerin patients with agermline BRCA mutation. N Engl J Med 2017;377:523-533.
40. Byrski T, Dent R, Blecharz P, et al. Results of a phase II open-label, non-randomized trial of cisplatin chemotherapy in patients with BRCA1-positive metastatic breast cancer. Breast Cancer Res 2012;14:R110-R110.
41. TuttA,Tovey H, Cheang MCU,etal.Carboplatin in BRCA1/2-mutated and triple-negative breast cancer BRCAness subgroups: the TNT Trial. Nat Med 2018;24:628-637.